{"ok":true,"trend":{"id":751507,"platform":"news","region":"global","key":"insilico medicine nominates ai-designed ism1354 gipr antagonist for obesity","title":"Insilico Medicine nominates AI-designed ISM1354 GIPR antagonist for obesity","url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxObXBCVWlFOHNJSFEyZWVaalFqRF8zaXlTZWVTOTFiZW9NQmdDWXl0TnJLejdUeHFCY0ZKUjI0ME50S2JfWUlRMzM3cFgweU0ydzVoaThkZ0tOY3gtM3d4bTVIRERQelVxbzlRZURTSmUzNmVlMkxtclJCTGxReGRrVXllbXFSaFl5RnV0NzhqQVRQMXhKWEVnZ2Vab25fN1MzaEFObXg1Ul8xdjhhd3NzaklLVnhNcEQyTXJ2VmdVUGtNa05PNy1LVg?oc=5","first_seen":"2026-10-02T15:56:33.379918Z","last_seen":"2026-10-02T21:25:32.655435Z","last_rank":26,"peak_rank":6,"last_volume":null,"peak_volume":0,"seen_count":5,"score":31.42,"category_hint":"medicine","section":"health","category":"medicine","summary":"Drug discovery company Insilico Medicine has nominated ISM1354, an AI-designed GIPR antagonist, as a preclinical drug candidate for the treatment of obesity. The compound was developed using the firm's artificial intelligence drug discovery platform, adding to a growing pipeline of AI-generated molecules advancing toward clinical development for metabolic disease.","why":"AI-designed drugs for obesity are drawing attention amid intense interest in new weight-loss therapies.","tone":"positive","entities":["Insilico Medicine","ISM1354","GIPR"],"summarized_at":"2026-10-02T21:59:53.540350Z","meta":{"via":"scan","lang":"en","term":"medicine","source":"Drug Target Review","published":"Fri, 02 Oct 2026 08:37:57 GMT"},"nw":null,"promo":null,"kind":null,"importance":null,"hidden":false,"hide_reason":null,"judged_at":null,"title_en":"Insilico Medicine picks AI-designed obesity drug candidate ISM1354","section_name":"Health","category_name":"Medicine","timeline":[{"captured_at":"2026-10-02T15:56:33.379918Z","rank":6,"volume":null},{"captured_at":"2026-10-02T17:18:32.688069Z","rank":11,"volume":null},{"captured_at":"2026-10-02T18:41:13.143913Z","rank":16,"volume":null},{"captured_at":"2026-10-02T20:03:13.067387Z","rank":22,"volume":null},{"captured_at":"2026-10-02T21:25:32.655435Z","rank":26,"volume":null}],"posts":[{"platform":"news","url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxObXBCVWlFOHNJSFEyZWVaalFqRF8zaXlTZWVTOTFiZW9NQmdDWXl0TnJLejdUeHFCY0ZKUjI0ME50S2JfWUlRMzM3cFgweU0ydzVoaThkZ0tOY3gtM3d4bTVIRERQelVxbzlRZURTSmUzNmVlMkxtclJCTGxReGRrVXllbXFSaFl5RnV0NzhqQVRQMXhKWEVnZ2Vab25fN1MzaEFObXg1Ul8xdjhhd3NzaklLVnhNcEQyTXJ2VmdVUGtNa05PNy1LVg?oc=5","author":"Drug Target Review","title":"Insilico Medicine nominates AI-designed ISM1354 GIPR antagonist for obesity","snippet":null,"posted_at":"2026-10-02T08:37:57Z","likes":null}],"elsewhere":[],"window":"7d"}}